TMC Life Sciences Berhad (KLSE: TMCLIFE)

Market Cap	975.45M
Revenue (ttm)	346.42M
Net Income (ttm)	40.65M
Shares Out	1.74B
EPS (ttm)	0.02
PE Ratio	24.03
Forward PE	n/a
Dividend	0.02 (3.96%)
Ex-Dividend Date	Dec 5, 2024

Volume	519,400
Open	0.555
Previous Close	0.560
Day's Range	0.550 - 0.560
52-Week Range	0.550 - 0.810
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About TMC Life Sciences Berhad

TMC Life Sciences Berhad, an investment holding company, provides healthcare services in Malaysia. The company operates Thomson Hospital Kota Damansara (THKD), a medical bedded center located in Selangor. Its THKD provides women and children health, cancer, orthopedics, ENT, head and neck laser, gastro, hepato, urology, fertility health services. In addition, the company’s reproductive treatment comprises in-vitro fertilisation, preimplantation genetic testing, fertility preservation, laparoscopic surgery, surgical sperm retrieval, and donation...

• Industry: Miscellaneous Health And Allied Services, Not Elsewhere Classified
• Founded: 1994
• Country: Malaysia
• Stock Exchange: Bursa Malaysia
• Ticker Symbol: TMCLIFE

Financial Performance

In 2024, TMC Life Sciences Berhad's revenue was 346.42 million, an increase of 11.19% compared to the previous year's 311.56 million. Earnings were 40.65 million, an increase of 3.54%.